SLV 337
Alternative Names: SLV337Latest Information Update: 15 Sep 2015
Price :
$50 *
At a glance
- Originator Solvay Pharmaceuticals
- Developer Abbott Laboratories; AbbVie
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 03 Dec 2010 Abbott completes a phase I/II trial (NCT00924534) in Type-2 diabetes mellitus in Bulgaria, Poland and South Africa
- 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories